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Abstract
Background: Testicular sex cord stromal tumors (SCSTs) are managed similarly to germ cell tumors (GCTs);
however, few studies have directly compared outcomes between these tumor types. Using the National Cancer
Database (NCDB), we sought to compare overall and stage-specific all-cause mortality (ACM) between SCSTs versus
GCTs.
Methods: NCDB was queried for patients diagnosed with SCSTs and GCTs between 2004 and 2013. Descriptive
statistics were used to compare sociodemographic and clinical characteristics between groups. Univariable and
multivariable Cox proportional hazards regression analyses were used to assess associations with ACM.
Results: We identified 42,192 patients diagnosed with testicular cancer between 2004 and 2013, with 280 having
SCSTs and 41,912 patients having GCTs. Median age for SCSTs and GCTs was 45 (interquartile range [IQR] 34–59)
and 34 (IQR 27–43), respectively (p < 0.001). Median follow-up was 39 and 52 months, respectively. Overall, patients
with SCSTs had greater risk of ACM compared to those with GCTs (HR 1.69, 95% CI 1.14–2.50). Private insurance,
greater education, and fewer comorbidities were associated with reduced risk of ACM (p < 0.05 for all). Among
those with stage I disease, tumor type was not associated with ACM on multivariable analysis. Among those with
stage II/III disease, patients with SCSTs had increased risk of ACM compared to patients with GCTs (HR 3.29, 95% CI
1.89–5.72).
Conclusions: Patients with advanced SCSTs had worse survival outcomes compared to those with advanced GCTs.
These data suggest a need for further investigation to ascertain effective management recommendations for SCSTs.
Keywords: Testicular neoplasms, Leydig cell tumors, Sertoli cell tumors, Sex cord-gonadal stromal tumors, Testicular
germ cell tumors
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Background
Testicular cancer is a rare form of cancer, representing
only 0.5% of new cancer cases in the United States (U.S.)
[1]. It most commonly occurs in young adults, with 5.9
new cases per 100,000 men between 2012 and 2016 [1].
Testicular tumors can be further subclassified based on
their cellular origin. Germ cell tumors (GCTs) account
for roughly 95% of all testicular tumors and include
seminomatous and nonseminomatous tumors (e.g., em-
bryonal, mixed germ cell) [2]. Sex cord stromal tumors
(SCSTs) make up the remaining 5% of testicular tumors
and include Leydig cell tumors (LCTs) and Sertoli cell
tumors (SCTs) [3].
SCSTs and GCTs differ greatly in their biological ag-
gressiveness and survival outcomes. GCTs have an excel-
lent prognosis, with a 99.7% 5-year disease-specific
survival among those with Stage I tumors [4]. Patients
with SCSTs appear to have worse survival outcomes,
with the 5-year overall survival of patients with Stage I
LCTs and SCTs being 91 and 77%, respectively [5]. This
survival difference is multifactorial, with the inherent
aggressiveness of SCSTs, differences in patient charac-
teristics, and variable response to treatment likely con-
tributing to this finding [6–8]. Prior studies focused on
SCSTs alone, primarily small series and case studies,
have demonstrated worse disease-specific and overall
survival outcomes, but few studies have directly com-
pared outcomes between SCSTs and GCTs [5, 9, 10].
These studies have been predominantly limited by the
rarity of these tumors and few mortality events reported
in large national cancer registries [5, 9].
Given that the American Urological Association
(AUA) provides formal guidelines for the management
of GCTs but none specific to SCSTs, the management of
SCSTs primarily reflects that of GCTs [11]. Thus, a sur-
vival comparison between these tumor types is critical to
identify whether a need for guidelines specific to SCSTs
is warranted. Using a large, nationwide database of can-
cer patients, we sought to compare total and stage-
specific all-cause mortality (ACM) outcomes between
patients with GCTs and SCTSs with consideration of
multiple sociodemographic and clinical characteristics.
Methods
Data source
The NCDB is a nationwide, facility-based cancer registry
started in 1989 as a joint program between the Commis-
sion on Cancer of the American College of Surgeons
and the American Cancer Society. It encompasses over
1500 institutions and contains over 70% of all cancer
diagnoses in the U.S. and Puerto Rico [12, 13]. This
study was approved by the Institutional Review Board at
the University of California, San Francisco.
Patient selection
Patients diagnosed between 2004 and 2013 were iden-
tified using the International Classification of Diseases
for Oncology, Third Edition (ICD-O-3) codes for
LCTs (8650), SCTs (8640), seminomas (9061), embry-
onal tumors (9070), and mixed germ cell tumors
(9085). Diagnosis was determined from microscopic
specimens, laboratory markers, imaging, or medical
records from participating institutions. Those with
unavailable staging information were excluded. Stage
was defined by Clinical Stage Group or Clinical
Pathological Group if the former was unavailable. Be-
cause of the low sample size of SCSTs, patients with
stage II and stage III disease were collapsed into one
group (stage II/III) for the survival analysis. We con-
sidered this a reasonable strategy, as both represent
tumors that have spread beyond the testicle. Further-
more, this strategy has been performed in prior litera-
ture [5]. For the same reason, all forms of therapy
received in addition to orchiectomy were grouped
into an “adjuvant therapy” category. Of note, NCDB
only reports first course treatments [14].
Objectives and statistical analysis
The primary endpoint was ACM. Demographic, clini-
copathologic, and overall survival outcome data was
collected. Survival time was calculated as the time in
months between diagnosis and either death or last
follow-up contact. Patient characteristics were com-
pared using Pearson’s chi-squared and Fischer’s exact
tests for categorical variables and Wilcoxon rank-sum
tests for non-parametric continuous variables. Survival
curves were generated using the Kaplan-Meier plot
method. Log-rank test and Cox proportional hazard
regression was used to compare differences in survival
among the entire cohort and on subgroup analysis by
tumor stage (stage I and stage II/III). The other vari-
ables included in the multivariable models included
tumor type, diagnosis year, race/ethnicity, insurance
type, annual household income, percent in the pa-
tient’s ZIP code without a high school diploma, resi-
dential environment (metropolitan versus urban/
rural), and Charlson-Deyo comorbidity score (CDS).
As the stage and adjuvant therapy variables violated
the proportionality assumption, analyses were strati-
fied on these variables (STATA 15 command: strata)
[15]. The results are presented as hazard ratios (HR)
with 95% confidence intervals (CI). HRs for patients
with unknown values are not reported but were in-
cluded in analyses to avoid selection bias secondary
to elimination of those patients. A p-value < 0.05 was
considered statistically significant. Analyses were per-
formed using STATA 15®.
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Results
Sociodemographic and clinical characteristics between
groups
Forty-two thousand one hundred ninety-two patients di-
agnosed with testicular cancer between 2004 and 2013
were identified (Table 1). There were 45 patients with
SCTs and 235 patients with LCTs for a total of 280 pa-
tients with SCSTs. There were 26,394 patients with
seminomas, 11,358 patients with embryonal tumors, and
4160 patients with mixed germ cell tumors for a total of
41,912 patients with GCTs. Median follow-up time was
39months (interquartile range [IQR] 20–61) for SCSTs
and 52months (IQR 28–79) for GCTs. Compared to pa-
tients with GCTs, patients with SCSTs tended to be
older (45 years IQR 34–59 versus 34 years IQR 27–43,
p < 0.001). Higher proportions of patients with SCSTs
were non-Hispanic Black (17% versus 3%) and were on
government insurance (25% versus 13%) (all p < 0.001).
Higher proportions of patients with SCSTs had one or
more comorbidities (10% versus 6%, p = 0.001) and had
stage I disease at diagnosis (93% versus 77%, p < 0.001).
A considerably lower proportion of patients with SCSTs
received adjuvant therapy in addition to orchiectomy
(6% versus 56%, p < 0.001). Type of adjuvant therapy re-
ceived in addition to orchiectomy by tumor type can be
seen in Supplementary Table 1.
The aforementioned observations remained true when
broken down by stage with a few exceptions (Table 2).
There was no statistically significant difference in race/
ethnic distribution or insurance status among those with
advanced disease. Notably, among those with advanced
disease, the magnitude of difference of the proportion of
those with one or more comorbidities was greater
among those with SCSTs (29% versus 7%, p < 0.001).
Survival analysis
On multivariable Cox proportional hazards regression of
the overall group, patients with SCSTs had greater risk
of ACM compared to those with GCTs (HR 1.68, 95%
CI 1.13–2.49, p = 0.010) (Table 3) on multivariable ana-
lysis adjusting for stage and treatment via stratification.
Compared to those with private insurance, those who
were uninsured (HR 2.31, 95% CI 2.01–2.66, p < 0.001)
or who had government insurance (HR 2.72, 95% CI
2.42–3.05, p < 0.001) had greater risk of ACM. Having
one or more comorbidities also conferred a greater risk
of ACM (HR 2.06, 95% CI 1.79–2.37, p < 0.001).
The Kaplan-Meier curves comparing overall survival
outcomes between tumors types by stage can be seen in
Fig. 1. At 1, 2, and 5 years, the overall survival rates for
stage I SCSTs was 99% (95% CI 96–100%), 96% (95% CI
92–98%), and 94% (95% CI 89–97%), respectively and
for stage I GCTs was 99% (95% CI 99–100%), 99% (95%
CI 99–99%), and 97% (95% CI 97–98%), respectively
Table 1 Overall comparison of the sociodemographic and
clinical characteristics of patients with SCSTs versus GCTs
Factor Overall cohort SCSTs GCTs p-value
N 42,192 280 41,912
Age at diagnosis,
median (IQR)
34 (27, 43) 45 (34, 59) 34 (27, 43) < 0.001
Diagnosis year 0.002
2004–2005 8215 (20%) 48 (17%) 8167 (20%)
2006–2007 8329 (20%) 39 (14%) 8290 (20%)
2008–2009 8520 (20%) 50 (18%) 8470 (20%)
2010–2011 8561 (20%) 81 (29%) 8480 (20%)
2012–2013 8567 (20%) 62 (22%) 8505 (20%)
Race/ethnicity < 0.001
Non-Hispanic White 32,565 (77%) 174 (62%) 32,391 (77%)
Non-Hispanic Black 1168 (3%) 48 (17%) 1120 (3%)
Hispanic/Other 7727 (18%) 55 (20%) 7672 (18%)
Unknown 732 (2%) 3 (1%) 729 (2%)
Insurance < 0.001
Uninsured 4786 (11%) 24 (9%) 4762 (11%)
Private insurance 31,092 (74%) 178 (64%) 30,914 (74%)
Medicaid/Medicare
/other
government insurance
5487 (13%) 70 (25%) 5417 (13%)
Unknown 827 (2%) 8 (3%) 819 (2%)
Income (per year) 0.42
Less than $38 k 5533 (13%) 45 (16%) 5488 (13%)
$38 k-62,999 20,324 (48%) 125 (45%) 20,199 (48%)
$63 k or greater 15,769 (37%) 106 (38%) 15,663 (37%)
Unknown 566 (1%) 4 (1%) 562 (1%)
Percent in ZIP code
without a high school
degree
0.81
21% or greater 6203 (15%) 42 (15%) 6161 (15%)
7–20.9% 23,172 (55%) 159 (57%) 23,013 (55%)
Less than 7% 12,287 (29%) 75 (27%) 12,212 (29%)
Unknown 530 (1%) 4 (1%) 526 (1%)
Residence 0.48
Metropolitan 35,048 (83%) 237 (85%) 34,811 (83%)
Urban/rural 7144 (17%) 43 (15%) 7101 (17%)
Charlson-Deyo
comorbidity score
0.001
0 39,825 (94%) 252 (90%) 39,573 (94%)
1 or more 2367 (6%) 28 (10%) 2339 (6%)
Stage < 0.001
Stage I 32,463 (77%) 259 (93%) 32,204 (77%)
Stage II 5478 (13%) 9 (3%) 5469 (13%)
Stage III 4251 (10%) 12 (4%) 4239 (10%)
Treatment received < 0.001
No orchiectomy 666 (2%) 2 (0.7%) 664 (2%)
Orchiectomy alone 17,885 (42%) 260 (93%) 17,625 (42%)
Orchiectomy +
adjuvant therapy
23,585 (56%) 18 (6%) 23,567 (56%)
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(log-rank p < 0.001). Among those with stage I disease,
tumor type was not associated with ACM on multivari-
able analysis (Table 4). High income (HR 0.74 among
those making >$63,000/year compared to those making
<$38,000/year, 95% CI 0.56–0.98, p = 0.032), was associ-
ated with lower ACM.
At 1, 2, and 5 years, the overall survival rates for stage
II/III SCSTs was 60% (95% CI 36–78%), 44% (95% CI
22–64%), and 25% (95% CI 8–47%), respectively and for
stage II/III GCTs was 95% (95% CI 95–96%), 92% (95%
CI 92–93%), and 89% (95% CI 88–90%) (log-rank p <
0.001). Among those with stage II/III disease, those with
SCSTs had a statistically significantly increased risk of
ACM (HR 3.28, 95% CI 1.88–5.73, p < 0.001) on multi-
variable analysis adjusting for treatment via stratification
(Table 4). Percent of individuals in the patient’s ZIP
code without a high school diploma (HR 0.67 for < 7%
compared to > 21, 95% CI 0.52–0.89, p = 0.004) was as-
sociated with ACM.
Discussion
Using a national registry of testicular cancer patients, we
found that SCSTs conferred increased risk of ACM
compared to patients with GCT. However, on multivari-
able subgroup analysis, this difference in overall survival
was limited to those with advanced (stage II/III) disease.
For these patients, the risk of ACM in the SCST group
was more than three times greater than that of the GCT
group. We also found that patients with SCSTs tended
to be older and were more frequently of Black race.
The association between SCSTs and worse survival
outcomes has been shown previously. Osbun et al. used
the Surveillance, Epidemiology, and End Results (SEER)
program database to estimate cancer-specific mortality
(CSM) for various testicular tumor types. They found a
lower overall CSM among patients with GCTs (2%)
compared to those with LCTs (7%) or SCTs (32%, p <
0.001) [9]. They also reported an observation of higher
unadjusted CSM rates in patients with SCSTs both in
stage I and stage III disease. As with our population,
higher proportions of SEER patients with SCSTs were
older and Black; however, in contrast to our population,
a higher proportion of SEER patients with SCSTs pre-
sented with advanced disease.
The finding that there is a greater risk of ACM with
SCSTs versus GCTs among patients with advanced dis-
ease regardless of receipt of adjuvant therapy use indi-
cates that management recommendations specific to
SCSTs are needed. Currently, the AUA provides guide-
lines for the management of seminomatous and non-
seminomatous GCTs but does not specifically address
SCSTs [11]. Thus, much of the management reflects that
of GCTs. An initial approach of radical resection for
early stage disease has been shown to be effective [6, 16].
Featherstone et al. reported that, among 36 patients with
SCSTs treated with orchiectomy alone, none progressed
to metastatic disease after a minimum follow-up period
of 2 years [16]. These results are consistent with the high
overall survival among patients with stage I disease, and
perhaps translation of management of SCSTs from that
of GCTs is appropriate.
Using GCTs as a reference, our data suggests that pa-
tients with disseminated SCSTs do not experience the
same relatively high overall survival rates as those with
localized disease. Although surgical management via
retroperitoneal lymphadenectomy may have modest effi-
cacy in those with established nodal disease, traditional
chemotherapy regimens used to treat GCTs like bleo-
mycin, etoposide, and cisplatin (BEP) or vinblastine, ifos-
famide, and cisplatin (VIP) have demonstrated a
transient response in SCSTs [6–8]. Radiotherapy also ap-
pears to be ineffectual for these tumors [8, 17]. This lack
of effectiveness signals an opportunity to investigate the
potency of newer chemotherapeutics, hormonal therap-
ies, and immunologic agents to improve outcomes for
patients with this rare tumor type. For example, it has
been demonstrated that glucocorticoid treatment may
inhibit a hormone-mediated cell growth mechanism in
LCTs that leads to tumor regression in murine models
[18]. Imatinib, a selective tyrosine kinase inhibitor, has
been shown to decrease viability of Leydig tumor cell
lines [19]. Furthermore, with the advent of the use of
genomics and precision medicine, future therapeutic
regimens could potentially be tailored for these patients
and may help improve treatment outcomes in patients
with advanced disease [20]. Necchi et al. performed
comprehensive genome profiling on the tumors of 10
patients with metastatic SCSTs and reported that, al-
though uncommon, several tumors expressed targetable
genomic alterations indicating the potential efficacy of
cell-cycle, mTOR, hedgehog, and polymerase inhibitors
[20]. A case-series by Calaway et al. reported that two
patients with disseminated SCSTs had tumor genetic
susceptibility testing following retroperitoneal lymph
Table 1 Overall comparison of the sociodemographic and
clinical characteristics of patients with SCSTs versus GCTs
(Continued)
Factor Overall cohort SCSTs GCTs p-value
Other/unknown 56 (0.1%) 0 (0%) 56 (0.1%)
Last contact or death,
months from diagnosis,
median (IQR)
N = 37,716 N = 249 N = 37,467
52 (28, 79) 39 (20, 61) 52 (28, 79) < 0.001
Time from diagnosis
to death in months,
median (IQR)
N = 1640 N = 27 N = 1613
20 (7, 43) 18 (7, 37) 20 (7, 43) 0.88
GCTs Germ cell tumors, IQR Interquartile range, SCSTs Sex cord stromal tumors
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Table 2 Stage-specific comparison of the sociodemographic and clinical characteristics of patients with SCSTs versus GCTs
Factor Stage I Stage II/III
SCSTs GCTs p-value SCSTs GCTs p-value
N 259 32,204 21 9708
Age at diagnosis, median (IQR) 43 (34, 57) 34 (28, 43) < 0.001 55 (42, 64) 33 (26, 42) < 0.001
Diagnosis year < 0.001 0.38
2004–2005 46 (18%) 6387 (20%) 2 (10%) 1780 (18%)
2006–2007 33 (13%) 6416 (20%) 6 (29%) 1874 (19%)
2008–2009 45 (17%) 6528 (20%) 5 (24%) 1942 (20%)
2010–2011 75 (29%) 6487 (20%) 6 (29%) 1993 (21%)
2012–2013 60 (23%) 6386 (20%) 2 (10%) 2119 (22%)
Race/ethnicity < 0.001 0.62
Non-Hispanic White 157 (61%) 25,125 (78%) 17 (81%) 7266 (75%)
Non-Hispanic Black 47 (18%) 809 (3%) 1 (5%) 311 (3%)
Hispanic/Other 52 (20%) 5672 (18%) 3 (14%) 2000 (21%)
Unknown 3 (1%) 598 (2%) 0 (0%) 131 (1%)
Insurance < 0.001 0.087
Uninsured 169 (65%) 3411 (11%) 4 (19%) 1351 (14%)
Private insurance 20 (8%) 24,575 (76%) 9 (43%) 6339 (65%)
Medicaid/Medicare/other
government insurance
62 (24%) 3605 (11%) 8 (38%) 1812 (19%)
Unknown 8 (3%) 613 (2%) 0 (0%) 206 (2%)
Income (per year) 0.38 0.68
Less than $38 k 40 (15%) 3981 (12%) 5 (24%) 1507 (16%)
$38 k-62,999 115 (44%) 15,408 (48%) 10 (48%) 4791 (49%)
$63 k or greater 100 (39%) 12,407 (39%) 6 (29%) 3256 (34%)
Unknown 4 (2%) 408 (1%) 0 (0%) 154 (2%)
Percent in ZIP code without a high
school degree
0.69 0.75
21% or greater 37 (14%) 4450 (14%) 5 (24%) 1711 (18%)
7–20.9% 147 (57%) 17,658 (55%) 12 (57%) 5355 (55%)
Less than 7% 71 (27%) 9716 (30%) 4 (19%) 2496 (26%)
Unknown 4 (2%) 380 (1%) 0 (0%) 146 (2%)
Residence 0.42 0.51
Metropolitan 221 (85%) 26,877 (84%) 16 (76%) 7934 (82%)
Urban/rural 38 (15%) 5327 (17%) 5 (24%) 1774 (18%)
Charlson-Deyo comorbidity score 0.016 < 0.001
0 237 (92%) 30,544 (95%) 15 (71%) 9029 (93%)
1 or more 22 (9%) 1660 (5%) 6 (29%) 679 (7%)
Stage 0.21
Stage I 259 (100%) 32,204 (100%) – –
Stage II – – 9 (43%) 5469 (56%)
Stage III – – 12 (57%) 4239 (44%)
Treatment < 0.001 < 0.001
No orchiectomy 0 (0%) 30 (0.1%) 2 (10%) 634 (7%)
Orchiectomy alone 250 (97%) 16,519 (51%) 10 (48%) 1106 (11%)
Orchiectomy + adjuvant therapy 9 (4%) 15,626 (49%) 9 (43%) 7941 (82%)
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Table 2 Stage-specific comparison of the sociodemographic and clinical characteristics of patients with SCSTs versus GCTs
(Continued)
Factor Stage I Stage II/III
SCSTs GCTs p-value SCSTs GCTs p-value
Other/unknown 0 (0%) 29 (0.1%) 0 (0%) 27 (0.3%)
Last contact or death, months from
diagnosis, median (IQR)
N = 229 N = 28,855 < 0.001 N = 20 N = 8612 0.002
41 (22, 62) 53 (29, 80) 19 (8, 55) 47 (24, 75)
Time from diagnosis to death, median (IQR) N = 13 N = 747 N = 14 N = 866
23 (18, 43) 31 (14, 58) 0.78 11 (7, 21) 13 (4, 28) 0.96
GCTs Germ cell tumors, IQR Interquartile range, SCSTs Sex cord stromal tumors
Table 3 Univariable and multivariable Cox proportional hazards regression analysis on the association between sociodemographic
and clinical characteristics and mortality of the overall cohort
Univariable HR (95% CI) Multivariablea HR (95% CI) – Overall
Tumor type
GCTs Ref. Ref.
SCSTs 2.96 (2.03–4.33)*** 1.68 (1.13–2.49)*
Age (per 5-year increase) 1.21 (1.19–1.23)*** 1.18 (1.16–1.20)***
Race/ethnicity
Non-Hispanic White Ref. Ref.
Non-Hispanic Black 1.80 (1.41–2.29)*** 1.13 (0.89–1.45)
Hispanic/other 1.27 (1.13–1.43)*** 1.14 (1.01–1.30)*
Insurance
Private insurance Ref. Ref.
Uninsured 2.63 (2.29–3.01)*** 2.32 (2.01–2.66)***
Medicaid/Medicare/other government insurance 4.33 (3.88–4.83)*** 2.72 (2.42–3.05)***
Income (per year)
< $38,000 Ref. Ref.
$38,000–$62,999 0.71 (0.62–0.81)*** 0.94 (0.82–1.09)
> $63,000 0.44 (0.38–0.50)*** 0.76 (0.63–0.92)**
Percent in ZIP code without a high school diploma
> 21% Ref. Ref.
7–20.9% 0.63 (0.56–0.71)*** 0.83 (0.73–0.96)*
< 7% 0.43 (0.37–0.49)*** 0.74 (0.61–0.90)**
Residence
Metropolitan Ref. Ref.
Urban/rural 1.49 (1.33–1.67)*** 1.13 (1.00–1.28)
Charlson-Deyo comorbidity score
0 Ref. Ref.
≥ 1 3.23 (2.82–3.70)*** 2.06 (1.79–2.37)***
CI Confidence interval, GCTs Germ cell tumors, HR Hazard ratio, IQR Interquartile range, SCSTs Sex cord stromal tumors
*p < 0.05
**p < 0.01
***p < 0.001
aThe following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code
without a high school diploma, residence, Charlson-Deyo comorbidity score
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node dissection. At the time of publication, one patient
was surviving on apalutamide for 4 months and another
was on everolimus with slightly regressing metastatic
disease for 12 months [21]. Finally, a step further would
be to enhance methods for distinguishing malignant
from benign LCTs for more directed adjuvant
treatments.
This study is not without limitations. The inclusion of
patients in this study assumes accurate designation of
ICD-O-3 coding by providers and misclassification may
bias the findings. This dataset also relies upon accurate
reporting of histology, as there is no central pathology
review. The NCDB has limited information on treatment
specifics (e.g., type of chemotherapeutic agent), schedule
Fig. 1 Kaplan-Meier survival estimates comparing all-cause mortality between patients with SCSTs versus GCTs among those with a) stage I
disease and b) stage II/III disease
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and sequence of treatment cycles, and does not provide
information on CSM. Despite these limitations, for those
with advanced disease the differences between ACM and
CSM rates are reduced. Additionally, the NCDB does
not contain information that may influence quality of
care received (e.g., hospital quality, surgeon experience,
patient healthcare access/literacy, etc.); however, many
factors that contribute to this (e.g., income, insurance,
education) were controlled for in our analysis. As this
study is a retrospective study based on an observational
dataset, there are unmeasured confounders which could
impact these findings. In addition, the small sample size
of SCSTs limited multivariable comparisons of ACM be-
tween SCST subtypes, and it has been proposed that
LCTs and SCTs may confer different degrees of ACM
risk [5]. The small sample size also precluded analysis by
adjuvant treatment type, which would help provide more
actionable data on the most effective management strat-
egy for these tumors. Along those same lines, our con-
clusion of survival differences between patients with
advanced SCSTs versus advanced GCTs is based on just
21 SCST patients. Despite its comparison to a large
group of GCT patients, this may limit the accuracy of
our conclusions and warrants future studies with larger
populations of SCST patients. The greater proportion of
stage III patients in the SCST group versus the GCT
group may have had an influence on survival; however,
the absolute difference between groups was quite small.
Additionally, the older age and greater proportion of pa-
tients with 1 or more comorbidity among those with ad-
vanced SCSTs could have been confounders in our
survival analysis; however, these differences should have
been controlled for in the multivariable model. Despite
these limitations, this study presents novel data compar-
ing testicular tumors types among a large number of pa-
tients with multiple sociodemographic and clinical
variables considered, and its findings may have import-
ant implications in altering management practices.
Conclusions
Among this cohort, when comparing SCSTs to GCTs,
patients with stage II/III disease but not stage I disease
was associated with a statistically significantly increased
risk of ACM on multivariable analysis. Increased ACM
in patients with advanced SCSTs indicates an imperative
for targeted treatment regimens specific to this unique
tumor type.
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Table 4 Multivariable Cox proportional hazards regression
analysis on the association between sociodemographic and
clinical characteristics and mortality by stage
Multivariablea HR
(95% CI) – Stage I
Multivariablea HR
(95% CI) – Stage II/III
Tumor type
GCTs Ref. Ref.
SCSTs 1.06 (0.60–1.86) 3.28 (1.88–5.73)***
Age (per 5-year increase) 1.23 (1.20–1.26)*** 1.13 (1.10–1.16)***
Race/ethnicity
Non-Hispanic White Ref. Ref.
Non-Hispanic Black 1.18 (0.80–1.72) 1.13 (0.81–1.56)
Hispanic/other 1.14 (0.95–1.38) 1.12 (0.94–1.32)
Insurance
Private insurance Ref. Ref.
Uninsured 2.58 (2.08–3.21)*** 2.07 (1.72–2.50)***
Medicaid/Medicare/other
government insurance
3.15 (2.64–3.75)*** 2.31 (1.97–2.70)***
Income (per year)
< $38,000 Ref. Ref.
$38,000–$62,999 0.92 (0.74–1.15) 0.96 (0.79–1.16)
> $63,000 0.74 (0.56–0.98)* 0.77 (0.61–1.02)
Percent in ZIP code without a high school diploma
> 21% Ref. Ref.
7–20.9% 0.87 (0.70–1.07) 0.80 (0.67–0.97)*
< 7% 0.80 (0.61–1.06) 0.68 (0.52–0.88)**
Residence
Metropolitan Ref. Ref.
Urban/rural 1.18 (0.98–1.42) 1.09 (0.91–1.29)
Charlson-Deyo comorbidity score
0 Ref. Ref.
≥ 1 2.03 (1.64–2.51)*** 2.03 (1.68–2.45)***
aThe following variables were included in the multivariable analysis: tumor
type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in
ZIP code without a high school diploma, residence, Charlson-Deyo
comorbidity score
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